$RichWire Markets and money, explained simply

LIVE

21:44 Modine Stock Surges 29% Following Reports of Samsung Acquisition Interest 21:39 Suncrete Holds Q3 2026 Earnings Call Describing Financial Results 21:39 Eagle Point Income Company Releases Third Quarter 2026 Financial Results 21:34 Evaluating Disney and Netflix Ahead of 2027: Financials and Strategy Compared 21:30 Nvidia Leadership Shakeup Tests Investor Confidence in the Artificial Intelligence Sector 21:30 AGNC Investment Grapples With Rising Rates and a 17.6% Yield 20:59 Lument Finance Trust Holds Third Quarter 2026 Earnings Discussion 20:58 VolitionRx Holds Third Quarter 2026 Earnings Conference Call 20:51 Klarna Shares Rise Following CFO Appointment and Upcoming Earnings Preview 20:42 ExxonMobil Shares Deliver Strong Gains Amid Middle East Oil Supply Pressures 20:36 Morgan Stanley Expands Digital Infrastructure with Vinyl Equity Buyout as M&A Activity Heats Up 20:35 Evaluating McDonald’s Valuation and Long-Term Market Potential 21:44 Modine Stock Surges 29% Following Reports of Samsung Acquisition Interest 21:39 Suncrete Holds Q3 2026 Earnings Call Describing Financial Results 21:39 Eagle Point Income Company Releases Third Quarter 2026 Financial Results 21:34 Evaluating Disney and Netflix Ahead of 2027: Financials and Strategy Compared 21:30 Nvidia Leadership Shakeup Tests Investor Confidence in the Artificial Intelligence Sector 21:30 AGNC Investment Grapples With Rising Rates and a 17.6% Yield 20:59 Lument Finance Trust Holds Third Quarter 2026 Earnings Discussion 20:58 VolitionRx Holds Third Quarter 2026 Earnings Conference Call 20:51 Klarna Shares Rise Following CFO Appointment and Upcoming Earnings Preview 20:42 ExxonMobil Shares Deliver Strong Gains Amid Middle East Oil Supply Pressures 20:36 Morgan Stanley Expands Digital Infrastructure with Vinyl Equity Buyout as M&A Activity Heats Up 20:35 Evaluating McDonald’s Valuation and Long-Term Market Potential

Topic: Peptides

Hims & Hers Stock Drops 17% on Weak Fourth-Quarter Guidance Amid Upcoming Peptide Expansion

Economy2 h ago

Hims & Hers Stock Drops 17% on Weak Fourth-Quarter Guidance Amid Upcoming Peptide Expansion

Shares of telehealth provider Hims & Hers tumbled 17% after fourth-quarter revenue guidance missed Wall Street projections, bringing the stock down over 40% for the year.

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.